You're describing a molecule known as **1,2-epoxy-3,4-dihydroxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene** (also sometimes called **3,4-dihydroxybenzo[c]phenanthrene 1,2-epoxide**).
Let's break down this molecule:
* **Benzo[c]phenanthrene:** This is a polycyclic aromatic hydrocarbon (PAH) with a specific arrangement of fused benzene rings.
* **Tetrahydro:** This indicates the presence of four hydrogen atoms added to the molecule, saturating some of the double bonds in the benzo[c]phenanthrene structure.
* **1,2-Epoxy:** This part signifies a three-membered ring containing an oxygen atom (an epoxide group) attached to the first and second carbons of the molecule.
* **3,4-Dihydroxy:** This means there are two hydroxyl groups (OH) attached to the third and fourth carbons of the molecule.
**Why is it important for research?**
This molecule is a **metabolite** of **benzo[c]phenanthrene**, a known **carcinogen**. Here's why it's important for research:
* **Carcinogenesis:** Understanding how benzo[c]phenanthrene is metabolized into this epoxide is crucial for studying its carcinogenic properties. Epoxides are highly reactive and can bind to DNA, potentially leading to mutations that can contribute to cancer development.
* **Mechanism of Action:** Researching this molecule helps scientists understand how specific metabolites of PAHs can interact with biological systems and potentially cause harm.
* **Biomarkers:** Measuring the levels of this molecule in biological samples (like urine or blood) can potentially serve as a **biomarker** for exposure to benzo[c]phenanthrene. This could be useful for monitoring environmental contamination or assessing occupational exposure.
* **Drug Development:** Understanding the metabolism and activity of this molecule could inspire the development of drugs that block or detoxify carcinogenic PAHs.
**Note:** While research on this specific molecule is important, it's crucial to remember that numerous other PAHs and their metabolites are also involved in carcinogenesis.
If you'd like to learn more about this molecule or its role in carcinogenesis, I recommend searching scientific databases like PubMed or searching for research papers on benzo[c]phenanthrene metabolism.
1,2-epoxy-3,4-dihydroxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene: RN given refers to compound with no isomeric designation; do not confuse with the tetrahydrobenz(a)anthracene analog [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 108184 |
| CHEMBL ID | 1743212 |
| MeSH ID | M0238389 |
| Synonym |
|---|
| 3,4-detbp |
| d-1,2-etbp |
| 111001-48-0 |
| 1,2-epoxy-3,4-dihydroxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene |
| benzo(c)phenanthrene-3,4-dihydrodiol-1,2-epoxide |
| b(c)phde |
| bcphde |
| CHEMBL1743212 |
| benzo[c]phenanthrene diol epoxide (bphde) |
| 1a,2,3,11d-tetrahydrobenzo(5,6)phenanthro(3,4-b)oxirene-2,3-diol |
| 3alpha,4beta-dihydroxy-1alpha,2alpha-epoxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene |
| benzo(5,6)phenanthro(3,4-b)oxirene-2,3-diol, 1a,2,3,11d-tetrahydro- |
| trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene |
| QGMAOLZIDYVIDK-UHFFFAOYSA-N |
| benzo(c)phenanthrene-3-.alpha.,4-.beta.-diol, 1,2,3,4-tetrahydro-1-.beta.,2-.beta.-epoxy-, (.+/-.)- |
| (.+/-.)-3-.alpha.,4-.beta.-dihydroxy-1-.beta.,2-.beta.-epoxy-1,2,3,4-tetrahydrobenzo(c)phenanthrene |
| trans-3,4-dihydroxy-anti-1,2,3,4-tetrahydrobenzo[c]phenanthrene |
| (.+/-.)-benzo(c)phenanthrene-3,4-diol-1,2-epoxide-1 |
| 1a,2,3,11d-tetrahydrobenzo[5,6]phenanthro[3,4-b]oxirene-2,3-diol # |
| 1a,2,3,11d-tetrahydrobenzo[5,6]phenanthro[3,4-b]oxirene-2,3-diol |
| DTXSID00911940 |
| 4-oxapentacyclo[9.8.0.02,8.03,5.014,19]nonadeca-1(11),2(8),9,12,14,16,18-heptaene-6,7-diol |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 20 (71.43) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 31 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||